Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$628M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$567M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$392M |
| 5 |
Walmart Inc
WMT
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$451M |
| 2 |
PepsiCo
PEP
|
+$382M |
| 3 |
Philip Morris
PM
|
+$256M |
| 4 |
Roku
ROKU
|
+$252M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.34% |
| 2 | Technology | 12.68% |
| 3 | Consumer Discretionary | 10.4% |
| 4 | Financials | 10.32% |
| 5 | Consumer Staples | 8.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGMO
2801
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $606K | ﹤0.01% |
67,000
-559,800
| -89% | -$6.28M |
|
2802
BioCryst Pharmaceuticals
BCRX
$2.51B
| $604K | ﹤0.01% |
+210,815
| New | +$656K |
|
|
NEOS
2803
DELISTED
Neos Therapeutics, Inc
NEOS
| $604K | ﹤0.01% |
408,162
+266,607
| +188% | +$431K |
|
|
SECO
2804
DELISTED
Secoo Holding Limited ADR
SECO
| $602K | ﹤0.01% |
8,990
-3,000
| -25% | -$222K |
|
2805
AXT Inc
AXTI
$5.07B
| $598K | ﹤0.01% |
168,000
-14,467
| -8% | -$55.7K |
|
|
RRTS
2806
DELISTED
RoadRunner Transportation Systems, Inc.
RRTS
| $597K | ﹤0.01% |
57,588
+12,500
| +28% | +$122K |
|
2807
Mannatech
MTEX
$9.78M
| $595K | ﹤0.01% |
34,017
+4,620
| +16% | +$75.4K |
|
|
MBAI
2808
Check-Cap
MBAI
$9.75M
| $593K | ﹤0.01% |
2,254
+58
| +3% | +$16.6K |
|
|
GNCA
2809
DELISTED
Genocea Biosciences, Inc.
GNCA
| $590K | ﹤0.01% |
203,362
+36,975
| +22% | +$126K |
|
2810
ProQR Therapeutics
PRQR
$262M
| $589K | ﹤0.01% |
102,300
+84,500
| +475% | +$675K |
|
2811
Vanguard FTSE All-World ex-US ETF
VEU
$70.6B
| $589K | ﹤0.01% |
11,800
-28,000
| -70% | -$1.4M |
|
|
MDP
2812
DELISTED
Meredith Corporation
MDP
| $587K | ﹤0.01% |
+16,000
| New | +$745K |
|
|
GLIBA
2813
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $584K | ﹤0.01% |
+9,410
| New | +$582K |
|
|
FLXN
2814
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $581K | ﹤0.01% |
+42,400
| New | +$503K |
|
|
GSUM
2815
DELISTED
Gridsum Holding Inc.
GSUM
| $581K | ﹤0.01% |
346,026
-761
| -0.2% | -$1.82K |
|
|
CRESY
2816
Cresud
CRESY
$759M
| $580K | ﹤0.01% |
104,824
+72,447
| +224% | +$549K |
|
2817
Boston Omaha
BOC
$436M
| $579K | ﹤0.01% |
29,200
+17,500
| +150% | +$373K |
|
|
TDAY
2818
USA Today Co
TDAY
$1.01B
| $576K | ﹤0.01% |
+65,404
| New | +$597K |
|
2819
Stagwell
STGW
$2.28B
| $576K | ﹤0.01% |
204,400
-28,000
| -12% | -$70.2K |
|
|
TCON
2820
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $576K | ﹤0.01% |
6,439
+393
| +7% | +$40.3K |
|
2821
Waste Management
WM
$90.5B
| $575K | ﹤0.01% |
+5,000
| New | +$584K |
|
2822
Twin Disc
TWIN
$355M
| $574K | ﹤0.01% |
54,193
+7,000
| +15% | +$83K |
|
|
SMIT
2823
DELISTED
Schmitt Industries Inc
SMIT
| $572K | ﹤0.01% |
261,048
+700
| +0.3% | +$1.49K |
|
2824
First Trust Natural Gas ETF
FCG
$639M
| $571K | ﹤0.01% |
+49,800
| New | +$610K |
|
2825
OneSpan
OSPN
$609M
| $571K | ﹤0.01% |
39,370
-70,299
| -64% | -$1.02M |
|
Similar funds
Jim Simons's Q3 2019 Portfolio in Review
As of Q3 2019, Jim Simons held 3,920 positions worth $118B, up 4% from $114B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $5.29B of net new capital in Q3 2019, opening 406 new positions and adding to 1,848 existing holdings. Its largest new stake was UnitedHealth: 1,624,826 shares worth $353M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $451M trimmed.
- Jim Simons's largest Q3 2019 buy was UnitedHealth: 1,624,826 shares worth $353M.
- Jim Simons added most to Celgene Corp in Q3 2019, an estimated $628M increase.
- Jim Simons's biggest Q3 2019 reduction was Apple, cutting an estimated $451M.
- Jim Simons fully exited Red Hat Inc in Q3 2019, selling an estimated $248M.
- Jim Simons's ten largest holdings make up 11% of its $118B portfolio in Q3 2019.
- Jim Simons opened 406 new positions and closed 522 in Q3 2019.
- Jim Simons's portfolio value rose 4% quarter-over-quarter to $118B.
Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.